REGENXBIO Inc

For the period ended Dec 31, 2024. Filed Mar 13, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 13, 2025

RGNX$7.69-4.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except per share data)

	Years Ended December 31,
	2024	2023	2022
Revenues
License and royalty revenue	$83,328	$90,242	$112,724
Total revenues	83,328	90,242	112,724
Operating Expenses
Cost of revenues	33,567	37,213	54,545
Research and development	208,522	232,266	242,453
General and administrative	76,619	88,494	85,281
Credit losses (recoveries)	(5,000)	—	—
Impairment of long-lived assets	2,101	—	—
Other operating expenses (income)	865	397	(6,679)
Total operating expenses	316,674	358,370	375,600
Loss from operations	(233,346)	(268,128)	(262,876)
Other Income (Expense)
Interest income from licensing	174	25	342
Investment income	18,729	11,319	5,383
Interest expense	(12,659)	(6,862)	(23,254)
Total other income (expense)	6,244	4,482	(17,529)
Loss before income taxes	(227,102)	(263,646)	(280,405)
Income Tax Benefit	—	152	84
Net loss	$(227,102)	$(263,494)	$(280,321)
Other Comprehensive Income (Loss)
Unrealized gain (loss) on available-for-sale securities, net	3,688	10,972	(12,832)
Total other comprehensive income (loss)	3,688	10,972	(12,832)
Comprehensive loss	$(223,414)	$(252,522)	$(293,153)
Net loss per share, basic and diluted	$(4.59)	$(6.02)	$(6.50)
Weighted-average common shares outstanding, basic and diluted	49,509	43,734	43,152

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.